Angle BioPharma

Angle BioPharma is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of next-generation cancer immunotherapies. The company leverages three core technology platforms: oncolytic herpes simplex virus (oHSV), mRNA-based therapeutics, and advanced cell therapies. Its lead product candidate, AG-01, is a genetically engineered oncolytic virus (oHSV-1) that expresses Granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce a potent anti-tumor immune response. AG-01 is currently being evaluated in Phase 2 clinical trials for various advanced solid tumors. Angle BioPharma's integrated approach combines viral vector engineering with nucleic acid delivery to address complex challenges in oncology. The company operates its own GMP-compliant manufacturing facilities to support its clinical pipeline and future commercialization efforts.